From Paris to India: How Novo Nordisk Is Trying to Rebuild Momentum After a Brutal Year
Published on 07/13/2026 at 05:34 | Redaktion boerse-global.de
When Novo Nordisk’s haemophilia candidate Denecimig took centre stage at the International Society on Thrombosis and Haemostasis congress in Paris last week, the company had more than just clinical data to present. The Danish drugmaker is fighting to restore investor confidence after a punishing twelve months that saw its shares shed more than a quarter of their value. New evidence from the FRONTIER4 study, combined with a chunky share buyback and a fresh market launch in India, has helped the stock claw back some of that lost ground. At Friday’s close of €43.32, the shares have surged 13.9% over the past 30 days — yet remain nearly 27% lower than a year ago.
The FRONTIER4 extension trial enrolled 426 patients aged one year and older with haemophilia A, tracking them for an average of six months for adults and adolescents and four months for children. The data showed a safety profile consistent with earlier phases: injection-site reactions were mild and transient, occurring in just 2.0% of paediatric doses and 1.8% of adult and adolescent doses. No neutralising antibodies emerged. On efficacy, 71% of adults and adolescents and 89% of children experienced zero treated bleeding episodes, with similar rates across weekly, bi-weekly and monthly dosing regimens. The flexible dosing schedule — once a month to once a week — is a key differentiator against Roche’s dominant Hemlibra (emicizumab), which lacks that breadth. Novo Nordisk submitted Denecimig to the US Food and Drug Administration in September 2025, and a decision is pending.
The Paris congress also saw updated long-term data on Concizumab (marketed as Alhemo), Novo Nordisk’s already-approved haemophilia drug for patients with inhibitors, with the Explorer10 trial tracking some patients for up to eleven years. The cumulative evidence is part of a broader push to challenge Roche’s hegemony in haemophilia A prophylaxis. Importantly, patients in the Denecimig studies could switch directly from Hemlibra without a washout or loading dose — a practical advantage that could ease adoption if approval comes.
While the pipeline news provided a near-term catalyst, the stock’s recovery rests on other pillars too. Novo Nordisk launched its weekly insulin Awiqli in India on 9 July, the seventh market globally. The weekly dose costs around $2.74, cutting annual injections from 365 to 52. The Indian insulin market is projected to grow from $660.5 million in 2025 to $916.4 million by 2034. Separately, the company withdrew a phase 2 comparative study for its CagriSema injection device, a minor setback in the obesity pipeline that has been overshadowed by the broader GLP-1 opportunity.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
On the US policy front, the Centers for Medicare & Medicaid Services kicked off its “Medicare GLP-1 Bridge” pilot on 1 July 2026, capping eligible Part D beneficiaries’ monthly costs for certain GLP-1 obesity drugs at $50 through the end of 2027. CVS Health followed in June, expanding its support for GLP-1 therapies and joining the Bridge programme. Still, CVS’s chief executive dampened enthusiasm on 12 July, cautioning that broader insurance coverage will require lower prices and stronger proof of long-term healthcare cost savings.
Novo Nordisk’s capital allocation strategy is also lending support. The 15 billion Danish kroner buyback launched in February had repurchased 23 million B-shares by 3 July at an average price of 270.32 kroner — around 6.2 billion kroner in total. Institutional sentiment has been mixed: Equitable Trust slashed its position by 72.2% in the first quarter, while Kornitzer Capital Management reduced by 35.1%.
Technically, the stock is showing renewed momentum without overheating. It trades 9.64% above its 50-day moving average of €39.51 and 6.69% above its 200-day moving average of €40.60. The 14-day relative strength index of 66.0 points to fresh buying interest but stops short of overbought territory. Yet the shadow of the old highs remains: at the 52-week peak of €60.95 reached in July 2025, the stock is still 28.93% lower. The 52-week trough of €30.25 from March 2026, by contrast, is now 43.21% below the current price.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
With half-year results due in August, Berenberg analysts anticipate a possible upward revision to Novo Nordisk’s full-year guidance, citing sustained demand for obesity treatments and a stabilising diabetes market. For a stock that has ricocheted between a high of €61 and a low of €30 in the span of sixteen months, the next few weeks will test whether the latest rally is a genuine recovery or merely a pause in the longer downturn.
Ad
Novo Nordisk Stock: New Analysis - 13 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
